Light AI Business Summary

Light AI Inc. (OHCFF) is a healthcare technology firm specializing in Software as a Medical Device (SaMD) that utilizes proprietary AI algorithms to transform standard smartphones into clinical-grade diagnostic tools. The company’s primary business segments focus on infectious disease diagnostics—specifically Group A Streptococcus (Strep A) and COVID-19—and wellness applications for conditions such as pink eye and skin ailments. Light AI generates revenue through a high-margin software-based model, primarily targeting licensing agreements with healthcare providers, telehealth platforms, and direct-to-consumer wellness subscriptions. Unlike competitors such as TytoCare, which requires proprietary peripheral hardware, or Healthy.io, which focuses on urinalysis and wound care, Light AI differentiates itself by offering a hardware-free, cloud-based imaging platform that achieves diagnostic-level accuracy (96.6% for Strep A) using only a smartphone camera. This positioning allows the company to scale rapidly in both developed markets and underserved regions where laboratory infrastructure is limited. The company is led by Chief Executive Officer John R. Luna, a 30-year medical technology veteran appointed in January 2026, who previously served as CEO of Nuheara and held executive roles at EssilorLuxottica. Founder Peter Whitehead, the visionary behind the market-leading VELscope oral cancer screening tool, currently serves as Chief Innovation Officer, focusing on the expansion of the company’s intellectual property and diagnostic library. The leadership team is supported by a high-pedigree Board of Directors, including Independent Chairman Steven Semmelmayer (former CEO of Denmat and Kerr Dental), Mark Attanasio (Founder of ATTA Elevators and Nocera Investment Corp), and Emmanuel Blin (CEO of TC4A and former executive at Bristol-Myers Squibb). Strategic advisory is further bolstered by capital markets veterans from Commodity Partners and Roadmap Capital, reflecting a strong institutional focus on global commercialization and regulatory navigation.